Shreepati Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 23-12-2024
- Paid Up Capital ₹ 0.46 M
as on 23-12-2024
- Company Age 29 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.75 Cr
as on 23-12-2024
- Revenue -23.13%
(FY 2022)
- Profit -52.76%
(FY 2022)
- Ebitda -31.86%
(FY 2022)
- Net Worth 12.90%
(FY 2022)
- Total Assets 4.85%
(FY 2022)
About Shreepati Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.46 M.
The company currently has active open charges totaling ₹2.75 Cr.
Vedant Muchhal, Dhiraj Muchhal, Rajesh Muchhal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232MP1995PTC009950
- Company No.
009950
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Sep 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- LocationIndore, M.P, Madhya Pradesh
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Shreepati Pharmaceuticals Pvt Ltd offer?
Shreepati Pharmaceuticals Pvt Ltd offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Nervous System and Antipsychotic API, Digestive System Drugs & Medicines, Laxatives, API (Active Pharmaceutical Ingredients).
Who are the key members and board of directors at Shreepati Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Muchhal  | Director | 16-Jun-1999 | Current |
| Vedant Muchhal | Director | 28-Mar-2016 | Current |
| Dhiraj Muchhal | Director | 28-Mar-2016 | Current |
| Rajesh Muchhal | Director | 16-Jun-1999 | Current |
Financial Performance of Shreepati Pharmaceuticals.
Shreepati Pharmaceuticals Pvt Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 23.13% decrease. The company also saw a substantial fall in profitability, with a 52.76% decrease in profit. The company's net worth Soared by an impressive increase of 12.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shreepati Pharmaceuticals?
Unlock access to Shreepati Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Shreepati Molecules Private LimitedActive 7 years 7 monthsRajesh Muchhal and Ravi Muchhal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Jan 2017 | ₹2.75 Cr | Open |
How Many Employees Work at Shreepati Pharmaceuticals?
Shreepati Pharmaceuticals has a workforce of 53 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shreepati Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shreepati Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
